The MYCN oncogene plays a central role in neuroblastoma development, with high expression inferring a poor prognosis. The MYCN regulatory network has been shown to serve as a promising drug target. In this project, I will study the novel candidate oncogene RRM2, which enables a replicative stress resistance phenotype in MYCN driven tumors, using in vivo and in vitro assays.